Steven Paladino - Henry Schein CFO, Executive VP and Executive Director
| HSIC Stock | USD 73.21 0.45 0.62% |
Director
Mr. Steven Paladino, CPA is Executive Vice President, Chief Financial Officer, Director of the Company. He is also a member of our Executive Management Committee. Prior to holding his current position, from 1993 to 2000, Mr. Paladino was Senior Vice President and Chief Financial Officer, from 1990 to 1992, he served as Vice President and Treasurer and, from 1987 to 1990, he served as Corporationrationrate Controller. Before joining us, Mr. Paladino was employed as a Certified Public Accountant for seven years, most recently with the international accounting firm of BDO Seidman LLP . Mr. Paladino brings to the Companys Board of Directors extensive financial, accounting and industry expertise and a strong, credible reputation within the financial industry. Mr. Paladinos responsibilities with the Company include the corporate oversight and strategic direction of business units as well as direct responsibility for corporate financial services. These corporate financial services include financial reporting, financial planning, treasury, investor relations, internal audit and taxation. Mr. Paladino also has responsibility for Henry Schein Financial Services and also works with the Corporationrationrate Business Development Group on mergers and acquisition activities. Mr. Paladinos skills in corporate finance and accounting, the depth and breadth of his exposure to complex financial issues and his longstanding relationships with the financial community are valued by the Board of Directors since 2000.
| Age | 67 |
| Tenure | 24 years |
| Address | 135 Duryea Road, Melville, NY, United States, 11747 |
| Phone | 631 843 5500 |
| Web | https://www.henryschein.com |
Henry Schein Management Efficiency
The company has return on total asset (ROA) of 0.0453 % which means that it generated a profit of $0.0453 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0888 %, meaning that it created $0.0888 on every $100 dollars invested by stockholders. Henry Schein's management efficiency ratios could be used to measure how well Henry Schein manages its routine affairs as well as how well it operates its assets and liabilities. As of April 25, 2024, Return On Tangible Assets is expected to decline to 0.07. In addition to that, Return On Capital Employed is expected to decline to 0.10. At present, Henry Schein's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 219.4 M, whereas Total Current Assets are forecasted to decline to about 2.4 B.Similar Executives
| Found 6 records | DIRECTOR Age | ||
| Argil Wheelock | EDAP TMS SA | 66 | |
| Joshua Disbrow | Zynex Inc | 42 | |
| Pierre Beysson | EDAP TMS SA | N/A | |
| Robrecht Michiels | EDAP TMS SA | N/A | |
| Michael Cress | Zynex Inc | 59 | |
| Barry Michaels | Zynex Inc | 66 | |
Management Performance
| Return On Equity | 0.0888 | ||||
| Return On Asset | 0.0453 |
Henry Schein Leadership Team
Elected by the shareholders, the Henry Schein's board of directors comprises two types of representatives: Henry Schein inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Henry. The board's role is to monitor Henry Schein's management team and ensure that shareholders' interests are well served. Henry Schein's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Henry Schein's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Ettinger, Senior Vice President - Corporate and Legal Affairs, Secretary | ||
| David McKinley, President Medical Group | ||
| Paul Rose, Senior Vice President Global Supply Chain | ||
| Norman Matthews, Independent Director | ||
| Philip Laskawy, Lead Independent Director | ||
| Steven Paladino, CFO, Executive VP and Executive Director | ||
| Ronald South, Senior CFO | ||
| Barry Alperin, Independent Director | ||
| Brad Connett, President - Henry Schein'sU.S. Medical Group | ||
| Shira Goodman, Independent Director | ||
| Lorelei McGlynn, Senior Vice President - Global Human Resources and Financial Operations | ||
| Bradley Sheares, Independent Director | ||
| Leonard David, Chief Compliance Officer, Senior Vice President | ||
| James Harding, CTO, Senior Vice President | ||
| Paul Brons, Independent Director | ||
| Lonnie Shoff, President and CEO of Global Animal Health and Strategic Partnerships Group | ||
| Gerald Benjamin, Chief Admin. Officer, Executive VP and Director | ||
| Bob Minowitz, President International Dental Group | ||
| Dianne Rekow, Director | ||
| Anne Margulies, Independent Director | ||
| Stanley Komaroff, Sr. Advisor | ||
| Mark Mlotek, Chief Strategic Officer, Executive VP and Director | ||
| Peter McCarthy, President - Global Animal Health Group | ||
| Bridget Ross, President of Global Medical Group | ||
| Kurt Kuehn, Independent Director | ||
| Christopher Pendergast, Senior Vice President CTO | ||
| James Breslawski, President, Executive Director and CEO of Global Dental Group | ||
| Elizabeth Rekow, Independent Director | ||
| Walter Siegel, Senior Vice President General Counsel | ||
| Graham Stanley, VP Officer | ||
| Jonathan Koch, Senior Vice President and CEO, Global Dental Group | ||
| Stanley Bergman, Executive Chairman and CEO | ||
| Joseph Herring, Independent Director | ||
| Olga Timoshkina, Chief Finance | ||
| Karen Prange, Executive Vice President; CEO of Global Animal Health, Medical and Dental Surgical Group | ||
| Carolynne Borders, Vice President - Investor Relations | ||
| Michael Racioppi, Senior Vice President Chief Merchandising Officer | ||
| Donald Kabat, Independent Director | ||
| Lawrence Bacow, Director | ||
| Louis Sullivan, Independent Director | ||
| Bradford Connett, Chief Group | ||
| Carol Raphael, Independent Director |
Henry Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Henry Schein a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0888 | ||||
| Return On Asset | 0.0453 | ||||
| Profit Margin | 0.03 % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 13.42 B | ||||
| Shares Outstanding | 128.48 M | ||||
| Shares Owned By Insiders | 0.84 % | ||||
| Shares Owned By Institutions | 99.16 % | ||||
| Number Of Shares Shorted | 5.5 M | ||||
| Price To Earning | 17.39 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Henry Schein. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Henry Stock refer to our How to Trade Henry Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for Henry Stock analysis
When running Henry Schein's price analysis, check to measure Henry Schein's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Henry Schein is operating at the current time. Most of Henry Schein's value examination focuses on studying past and present price action to predict the probability of Henry Schein's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Henry Schein's price. Additionally, you may evaluate how the addition of Henry Schein to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
Is Henry Schein's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Henry Schein. If investors know Henry will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Henry Schein listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.62) | Earnings Share 3.16 | Revenue Per Share 94.466 | Quarterly Revenue Growth (0.10) | Return On Assets 0.0453 |
The market value of Henry Schein is measured differently than its book value, which is the value of Henry that is recorded on the company's balance sheet. Investors also form their own opinion of Henry Schein's value that differs from its market value or its book value, called intrinsic value, which is Henry Schein's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Henry Schein's market value can be influenced by many factors that don't directly affect Henry Schein's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Henry Schein's value and its price as these two are different measures arrived at by different means. Investors typically determine if Henry Schein is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Henry Schein's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.